A study to investigate the exposure of budesonide, glycopyrronium, and formoterol (BGF) delivered by hydrofluoroolefin (HFO) propellant metered dose inhaler (MDI) compared to a hydrofluoroalkane (HFA) propellant MDI in healthy adults

Trial Identifier:	D598AC00001
Sponsor:	AstraZeneca
Collaborator:	Parexel
Start Date:	January 2025
Primary Completion Date:	June 2025
Study Completion Date:	June 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
US, MD	Brooklyn, MD, US, 21225

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.